Benign Hematologic Conditions

Immune Thrombocytopenia

Advarra IRB #H-41733/ Takeda #TAK-079: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Persistent/Chronic Primary Immune Thrombocytopenia (pending Advarra IRB approval)